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Abstract
The G-protein coupled estrogen receptor 30 (GPR30) is a seven-transmembrane domain receptor that mediates rapid
estrogen responses in a wide variety of cell types. This receptor is highly expressed in the cardiovascular system, and exerts
vasodilatory effects. The objective of the present study was to investigate the effects of GPR30 on vascular responsiveness in
diabetic ovariectomized (OVX) rats and elucidate the possible mechanism involved. The roles of GPR30 were evaluated in
the thoracic aorta and cultured endothelial cells. The GPR30 agonist G1 induced a dose-dependent vasodilation in the
thoracic aorta of the diabetic OVX rats, which was partially attenuated by the nitric oxide synthase (NOS) inhibitor, nitro-L-
arginine methylester (L-NAME) and the GPR30-selective antagonist G15. Dose-dependent vasoconstrictive responses to
phenylephrine were attenuated significantly in the rings of the thoracic aorta following the acute G1 administration in the
diabetic OVX rats. This effect of G1 was abolished partially by L-NAME and G15. The acute administration of G1 increased
significantly the eNOS activity and the concentration of NO in the endothelial cells exposed to high glucose. G1 treatment
induced an enhanced endothelium-dependent relaxation to acetylcholine (Ach) in the diabetic OVX rats. Further
examination revealed that G1 induced vasodilation in the diabetic OVX rats by increasing the phosphorylation of eNOS.
These findings provide preliminary evidence that GPR30 activation leads to eNOS activation, as well as vasodilation, to a
certain degree and has beneficial effects on vascular function in diabetic OVX rats.
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Introduction
A novel estrogen receptor GPR30, which belongs to the family
of seven-transmembrane G-protein-coupled receptors, exhibit
various rapid biological responses to estrogen [1]. GPR30 has
recently been identified to be expressed in the vascular system
[2,3]. Recent studies have demonstrated that the GPR30-specific
agonist G1 [4] and the GPR30-selective antagonist G15 [5], which
are mainly used to study the role of GPR30 in the cardiovascular
system [2], elicits the relaxation of the carotid artery [3], and G1
infusion results in an acute reduction in arterial blood pressure [6].
In addition, vasorelaxation is dependent on endothelium-derived
nitric oxide (NO) [3,7]. GPR30 also plays a critical role in
improving glucose-stimulated insulin release while suppressing
glucagon and somatostatin secretion [8,9]. These effects may help
reveal a potential novel therapeutic strategy for vascular dysfunc-
tion in diabetes mellitus.
Endothelial cells provide a functional barrier and modulate
several signals involved in vasomotion. A number of clinical trials
for diabetes mellitus have shown that hyperglycemia is a major
causal factor in the development of endothelial dysfunction [10].
The slow reactions of hyperglycemia to endothelial cells results in
insufficient NO and impairment of endothelium-dependent
vasodilation [11].
Endothelial production of NO is critical to the regulation of
vascular responses, including regional blood flow and vascular
tone, vascular smooth muscle cell proliferation, platelet adhesion,
and aggregation and leukocyte-endothelial interactions [12].
eNOS knockout mice show several phenotypes [12], including
the lack of endothelium-derived relaxing factor activity and
hypertension [13], increased platelet aggregation [14], increased
vascular smooth muscle cell proliferation [15], atherosclerosis [16],
increased propensity to thrombosis, and leukocyte-endothelial
adhesion [17].
Hence, the aim of the present study was to explore whether G1
administered at the same dose as previously described that induced
dose-dependent relaxations at aorta [6], carotid [3] and mesen-
teric arteries [7] can also induce vasodilatory effects on the
thoracic aorta with vascular endothelial dysfunction in a diabetic
condition and prevent the vascular endothelial dysfunction
observed in ovariectomized (OVX) diabetic rats. Moreover, the
aim of the present study was to examine the effect of G1
replacement on vascular function in diabetic OVX rats.
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Effect of GPR30 activation on metabolic parameters
Although all rats were weight-matched at the beginning of the
experiment, the body weights of the diabetic OVX rats were less
than those of the normal OVX rats. G1 treatment (200 mg/kg,
i.p., 2 times per day, 8 weeks) increased significantly the body
weights of the diabetic OVX rats (Fig. 1A). The plasma glucose
levels increased significantly in the diabetic OVX rats compared
with those in the OVX rats during the 8 weeks period. However,
G1 treatment reduced the plasma glucose level in the diabetic
OVX rats (Fig. 1B). The serum insulin levels of four groups was
not significantly different (Fig. 1C), although, the serum insulin
levels was increased slightly in diabetic OVX rats. However,
diabetic OVX rats display a decrease in NO serum levels
compared with OVX rats. G1 treatment increased NO serum
levels compared with the diabetic OVX rats (Fig. 1D).
Activation of GPR30-induced relaxation in the thoracic
artery of the OVX and diabetic OVX rats
Bath application of G1 (1 nM -10 mM) induced strong
relaxation of the aortic rings from the OVX rats in a dose-
dependent manner (Fig. 2A). And, G1 also induced relaxation of
the aortic rings from the diabetic OVX rats in a dose-dependent
manner (Fig. 2C). The effect of G1 in the absence or presence of
the NOS inhibitor L-NAME (100 mM) and the GPR30-selective
antagonist G15 (1 mM) [5,18] were detected to identify the role of
NO on GPR30-mediated vasorelaxation. The vascular relaxation
induced by G1 was partly abolished by L–NAME and abolished
by G15 in the aortic strips from the OVX and diabetic OVX rats
(Fig. 2A, C). Last, western blot analysis was performed in these
aortic rings. Bath application of G1 increased significantly the
phosphorylation level of eNOS in the aortic strips from the OVX
and diabetic OVX rats, and the phosphorylation level of eNOS
induced by G1 was also attenuated by G15 (Fig. 2B, D).
Effect of GPR30 activation on the contraction response to
phenylephrine (PE) in the thoracic arteries of the diabetic
OVX rats
In present study, the maximum constriction of PE of the aortic
rings from the OVX rats is slightly lower than that of diabetic
OVX rats. But, no significant difference was found in either the
sensitivity to or the maximum constriction of PE (1 mM) between
the OVX and diabetic OVX rats, which indicated that diabetes
had no significant effect on the vasoconstrictor responses of aortic
segments to PE in our experiment (Fig. 3A). G1 (3 mmol/L)
treatment dilated significantly the thoracic arteries in the presence
of PE, compared with the OVX or diabetic OVX group (Fig. 3A).
To explore the possible mechanism underlying the G1-induced
vasoactive response, we examined the transient vasoconstrictor
response to PE in the presence of L–NAME (100 mM) and G15
(1 mM). The vascular relaxation induced by G1 in the presence of
PE was partly abolished by L–NAME and abolished by G15 in the
diabetic OVX rats (Fig. 3A). Western blot showed that diabetes
depressed markedly the phosphorylation level of eNOS in the
OVX rats. However, G1 treatment raised significantly the
phosphorylation level of eNOS, compared with the OVX or
diabetic OVX rats, and G15 blocked the effect of G1 on eNOS
phosphorylation (Fig. 3B).
Effect of chronic G1 administration on the relaxation
response to ACh or SNP in the thoracic arteries of the
diabetic OVX rats
When the PE-induced contraction had reached a plateau in
organ chambers, ACh (10
29 Mt o1 0
25 M) or SNP (10
29 Mt o
10
25 M) was added cumulatively. The capability of the concen-
tration-dependent relaxation induced by ACh, with the maximum
response at 10
25 M, was weaker in the aortic segments from the
diabetic OVX rats than those from the OVX rats (Fig. 4A). After
the chronic administration of G1 (200 ug/kg p.i. 2/per day), the
capability of ACh-induced relaxation in the aortic segments from
the diabetic OVX rats was enhanced significantly. The capability
of the relaxation caused by SNP (10
29 Mt o1 0
25 M) had no
difference in the aortic segments among the three groups (Fig. 4B).
The expressions of GPR30 and eNOS protein in
endothelial cells and aortas
The endothelial cells displayed a positive immunostaining for
GPR30 (Fig. 5A). We next examined the expressions of GPR30
and eNOS in the endothelial cells by Western blotting. In
endothelial cells, the GPR30/b-actin ratio was decreased in the
high glucose media for 72 h, compared with that in the samples in
the low glucose media (Fig. 5B). In addition, we also evaluated the
expression of GPR30 and eNOS protein in aortas from OVX and
diabetic OVX rats. The expression of the GPR30 was also
decreased in aortas from diabetic OVX rats (versus OVX rats)
Figure 1. Effects of G1 on body weight, blood glucose, serum
insulin and serum NO of diabetic OVX rats. (A) Body weight was
significantly decreased in OVX rats treated with STZ (n=6) as compared
with those in OVX rats (n=20). G1 (200 mg/kg, i.p., 2 times per day, 8
weeks) administration (n=6) attenuated the body weight loss in OVX
rats treated with STZ. (B) Blood glucose was increased in OVX rats
treated with STZ (n=6) as compared with those in OVX rats (n=20). G1
administration (n=6) decreased the high blood glucose impairment in
OVX rats treated with STZ. (C) The serum insulin levels had no
difference among the four groups. (D) Diabetic OVX rats (n=6) display
a decrease in NO serum levels compared with those in OVX rats (n=20).
G1 administration (n=6) increased NO serum levels compared with
diabetic OVX rats.
*p,0.05,
**p,0.01 compared with OVX rats;
#p,0.05
compared with diabetic OVX rats.
doi:10.1371/journal.pone.0038787.g001
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endothelial cells and aortas (Fig. 5B, C).
Effect of G1 on eNOS enzymatic activity in endothelial
cells
The effect of G1 on eNOS activation was examined to explore
the potential signaling pathways contributory to the G1-evoked
vasodilation. The cultured endothelial cells treated with G1
(10 nM) in serum-free medium. The amounts of phosphorylated
eNOS in endothelial cells were detected by Western blot (Fig. 6A).
G1 activated the eNOS phosphorylation after a 5 min to 10 min
treatment. The increased level was maintained up to about
30 min, followed by a reduction at 1 h (Fig. 6A). We also
investigated the influence of G1 on the activation of eNOS in the
cultured endothelial cells exposed to high glucose. The phosphor-
ylation levels of eNOS decreased significantly when the endothe-
lial cells were treated with 33 mM of glucose for 48 h or 72 h
(Fig. 6B). However, high concentration of mannitol (33 mM) did
not alter the phosphorylation level of eNOS (Fig. 7A). Following
the high glucose treatment, application of G1 (10 nM, 10 min)
reversed the down-regulation of phosphorylation level of eNOS by
high concentration of glucose (Fig. 6B; Fig. 7A).
Effect of NOS inhibitor and GPR30-selective antagonist
on the NO release in endothelial cells
The possible involvement of GPR30 in the NO release in the
endothelial cell was determined by preincubating the endothelial
cells in high glucose for 48 h, followed by treatment with L–
NAME (100 mM) for 40 min or without L-NAME, or with G15
for 15 min or without G15, and thereafter treated with G1
(10 nM) for 10 min or without G1. The phosphorylation level of
eNOS decreased significantly in the endothelial cells exposed to
high glucose. G1 increased evidently the phosphorylation level of
eNOS of endothelial cells in the presence of high glucose. The
effect of G1 on eNOS phosphorylation was blocked by G15
(Fig. 7A). In addition, the NO release was detected by Nitric
Oxide Assay Kit (Fig. 7B). NO production decreased significantly
in the endothelial cells exposed to high glucose. G1 evidently
Figure 2. G1-induced relaxation in the thoracic artery in a dose-dependent manner. (A) G-1 (1 nM -10 mM) dilated the arteries from the
OVX rats in a dose-dependent manner; however, L-NAME (100 mM) and G15 (1 mM) partially abolished the effect of G1. n=6 rings from 3 rats. (B)G 1
increased the phosphorylation level of eNOS (p-eNOS; at serine1177) in arteries from OVX rats, and the phosphorylation level of eNOS induced by G1
was partially attenuated by G15. (C) G-1 (10 nM -100 mM) dilated the arteries from the diabetic OVX rats in a dose-dependent manner; however, L-
NAME (100 mM) and G15 (1 mM) abolished the effect of G1. n=6 rings from 3 rats. (B) G1 increased the phosphorylation level of eNOS (p-eNOS; at
serine1177) in arteries from diabetic OVX rats, and the phosphorylation level of eNOS induced by G1 was partially attenuated by G15.
*p,0.05
compared with OVX rats;
#p,0.05 compared with OVX+G1 rats;
$p,0.05 compared with diabetic OVX rats;
**p,0.01 compared with OVX rats;
&p,0.05 compared with diabetic OVX+G1 rats. Results are given as the mean 6 SEM of three independent experiments.
doi:10.1371/journal.pone.0038787.g002
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presence of high glucose. The effect of G1 on NO production was
blocked by L-NAME and G15 (Fig. 7B). High concentration of
mannitol (33 mM) did not alter the NO production (Fig. 7B).
Discussion
The present study yielded the following novel findings: (1) G1
treatment reduced blood glucose and ameliorated the diabetes-
induced loss in body weight and NO serum levels in the diabetic
OVX rats; (2) Administration of G1 for 8 wk could partially
prevent the functional changes on vascular reactivity in the
diabetic OVX rats; (3) The dose-dependent vasoconstrictor
responses to PE are significantly attenuated following the acute
G1 administration in the diabetic OVX rats; and (4) The
activation of GPR30 induced the phosphorylation of eNOS,
which enhanced the NO-dependent vasodilation. The results
suggest that the activation of GPR30 activation has the potential to
improve the vascular function in diabetes.
The body weights of the diabetic OVX rats were less than those
of the OVX rats. G1 treatment increased the body weights,
decreased blood glucose and ameliorated nitric oxide serum levels
in type 2 diabetic rats induced by a high-fat diet combined with
low doses of streptozotocin. These findings suggest that G1 has an
antidiabetic effect. Recent studies have shown that E2 and G-1
improved insulin secretion [8,9,19]. The mechanism of the
antidiabetic action may be through activation of the epidermal
growth factor receptor and ERK [8], and anti-apoptotic effects in
pancreatic islets [19] by GPR30. In addition, depression of
glucagon and somatostatin secretion may also play a critical role in
the secretion of insulin [9].
Endothelial production of NO is critical to the regulation of
vascular responses. The reduction in the activity of eNOS may
result in the lower production of NO. It is also known that the
phosphorylation of eNOS contributes to the regulation of eNOS
activity [20]. Among the regulatory eNOS phosphorylation sites,
Ser
1177 is the one that is most extensively studied [20]. And, a lot
of stimuli that promote eNOS activation can cause phosphoryla-
tion of this site. Both basal and stimulated NO synthesis will be
reduced by preventing eNOS phosphorylation at Ser
1177 by
mutating the site to alanine [21]. Diabetes mellitus is associated
with the endothelial dysfunction and bioavailabilty of NO. The
phosphorylation level of eNOS was detected to explore further the
molecular mechanisms of GPR30. eNOS activity depends on
eNOS phosphorylation, which Ser
1,177 has characterized exten-
Figure 3. G1 pretreatment on the contraction response to PE in
diabetic OVX rats. (A) There was no difference on contraction of
thoracic aorta between OVX and diabetic OVX groups. G1 (3 mmol/L)
treatment dilated the thoracic arteries in the presence of PE (1 mM) in
diabetic OVX rats. L–NAME (100 mM) and G15 (1 mM) abolished the
effect of G1 in the diabetic OVX rats as shown by the maximal response
(Emax) to PE. The sensitivity of arteries to PE (pD2) did not change
among groups. (B) The eNOS phosphorylation was significantly
reduced in OVX diabetic group as compared with OVX group. G1
treatment increased the eNOS phosphorylation; whereas, G15 blocked
the eNOS phosphorylation induced by G1. n=6–12 rings from 4–6
rats.
*p,0.05 compared with OVX rats;
##p,0.01 compared with
diabetic OVX+G1 rats;
$$p,0.01 compared with diabetic OVX rats.
R e s u l t sa r eg i v e na st h em e a n6 SEM of three independent
experiments.
doi:10.1371/journal.pone.0038787.g003
Figure 4. Effect of G1 on the relaxation response to ACh or
SNP. (A) Capability of the relaxation induced by ACh (10
29 Mt o
10
25 M) was reduced in diabetic OVX rats as compared with OVX rats.
Long-term administration of G1 (200 ug/kg i.p., 2/per day, 8 weeks)
increased the capability of vasorelaxation as shown by the Emax and
pD2.( B) The capability of the relaxation caused by SNP (10
29 Mt o
10
25 M) had no difference in the aortic segments among the three
groups. n=6–12 rings from 5–8 rats.
**p,0.01 compared with OVX rats;
#p,0.05 compared with diabetic OVX rats. Results are given as the
mean 6 SEM of three independent experiments.
doi:10.1371/journal.pone.0038787.g004
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production in the endothelial cells. L-NAME or G15 not only
attenuated the effect of G1 on the vasodilation of the thoracic
aorta, but also reduced the release of NO. In addition, G15 also
can reduce G1-evoked eNOS phosphorylation. These findings
suggest that the endothelium-dependent relaxation induced by G1
may be caused by the eNOS activity, which is consistent with the
study reported by Meyer [23]. In addition, acute G1 administra-
tion also dilated the thoracic arteries exposed to PE in the diabetic
OVX rats. When the aortic rings of the diabetic OVX rats were
incubated with L-NAME and G1, L-NAME abolished partially
the effect of G1 in the presence of PE. These results suggest that
the enhancement of PE-induced contractile responses in the aortas
of the diabetic OVX rats may be caused by a diabetes-related
impairment of the endothelial NO generation, and G1 can
attenuate this impairment in the endothelial cells through the
eNOS signaling pathway. This phenomenon is consistent with the
results in several recent studies [2,3,6,7,24,25] that have reported
that the activation of eNOS phosphorylation is involved in the
relaxation of the aortic rings induced by G1.
The results of the current study indicate that G1 induces a
vasorelaxation in the thoracic aortas of the diabetic OVX rats,
which is blocked partially by the NOS inhibitor(L-NAME) or the
GPR30-selective antagonist (G15). Hence, we considered the
possibility of partial reversal of endothelial dysfunction by GPR30.
The assessment of physiologic vasodilator responses can measure
endothelial dysfunction [26]. Previous studies have reported that
the forearm blood flow response to ACh is reduced in patients with
type 2 diabetes, suggesting endothelial dysfunction [27–29]. The
results of the present study indicate that ACh-induced vasodilation
is markedly blunted in the diabetic OVX rats, but recovered
partially after the chronic administration of G1. A preliminary
report have indicated that G1 reduces levels of superoxide [3].
Vascular dilation caused by ACh is also reported to depend on the
NO produced by the endothelium [12].
In the current study, we report for the first time that G1
increased eNOS phosphorylation in the endothelial cells. Pre-
treatment with high glucose resulted in a significant decrease in
NO, compared with the control. Incubation with G1 could restore
NO production. Furthermore, G15 suppressed effectively the G1-
induced activation of eNOS and decreased NO production. These
results indicate that G1 increases the NO availability via eNOS
phosphorylation. Furthermore, the results of the present study
confirmed that at least part of the vasodilation of G1 is linked to
the release of NO [3,7].
Insufficient endothelial NO availability is known to be an
important mechanism underlying endothelial dysfunction [30],
with conditions conducive to the development of atherosclerosis,
vasoconstriction, thrombosis, inflammation, and neointimal pro-
liferation [12]. Thus, the reduction in eNOS phosphorylation is an
important cause of endothelial dysfunction [31,32]. Moreover, G1,
a selective agonist of GPR30, may improve vascular function by
enhancing NO availability. These biological actions support the
idea of GPR30 as a vascular protection factor. However, the role
of GPR30 in vascular health and its functions or molecular
mechanisms need further investigation.
In summary, the activation of GPR30 elicits an endothelium-
dependent, NO-mediated vascular relaxation in the thoracic aorta
of diabetic OVX rats, and chronic G1 treatment could prevent
vascular endothelial dysfunction in the diabetic OVX rats. Given
that endothelial NO has a crucial role not only in modulating
vascular tone but also in antiatherosclerosis [12], we can speculate
that increased NO bioavailability induced by G1 could also
participate in the inhibited atherosclerotic process in diabetic
OVX rats.
Figure 5. The expressions of GPR30 and eNOS protein in
endothelial cells and aortas. (A) GPR30 expression in endothelial
cells from intact SD female rats (red=GPR30). (B) Western Blot analysis
of GPR30 and eNOS expression showed that cultures of the endothelial
cells maintained in high glucose (HG, 33 mM) showed reduction in
GPR30 expression compared to normal glucose (NG, 5 mM). (C) Western
Blot analysis of GPR30 and eNOS expression also showed reduction in
GPR30 expression in the aortas from diabetic OVX rats compared to
those from diabetic OVX rats.
*p,0.05 compared with NG;
#p,0.05
compared with OVX rats. Results are given as the mean 6 SEM of three
independent experiments.
doi:10.1371/journal.pone.0038787.g005
Figure 6. Effect of G1 on eNOS enzymatic activity in
endothelial cells. (A) The endothelial cells were cultured in vitro,
and treated with G1 (10 nM) for 5, 10, 25, 60, 180 min. G1 activated
eNOS phosphorylation after 5–10 min treatment. The increased level
was maintained up to 30 min, followed by a reduction at 1 h.
**p,0.01
compared with control. (B) Endothelial cells were exposed to high
glucose concentration (33 mM) for 48 or 72 h, and then incubated with
G1(10 nM) for 10 min. G1 treatment (10 nM, 10 min) reversed the
down-regulation of phosphorylation level of eNOS by high concentra-
tion of glucose.
*p,0.05 compared with the glucose treated before;
#p,0.05 compared with the glucose treated at 48 h or 72 h without
G1. Results are given as the mean 6 SEM of three independent
experiments.
doi:10.1371/journal.pone.0038787.g006
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Animal
Six-week-old Sprague-Dawley female rats weighing approxi-
mately 200 g were maintained on a 12 h light/dark cycle at a
constant room temperature (22uC61uC). Bilateral ovariectomy
was performed on all animals with 3% pentobarbital sodium
anesthesia. To induce diabetes mellitus, the rats were fed with
high-fat diet (HFD) after ovariectomy for 2 months, and then were
injected intraperitoneally with streptozotocin (STZ, 30 mg/kg)
(Sigma-Aldrich, St. Louis, MO, USA), which was dissolved in
sodium citrate buffer (pH 4.2). The control rats were fed with
normal rodent diet, which were injected with a similar volume of
citrate buffer. The composition of the normal rodent diet was 20%
protein and 4.5% fat. The HFD diet was composed of 21.2%
protein, 12% fat, 15% sucrose, and 1% cholesterol. The blood
glucose concentrations were measured by a glucometer (Accu-
trend; Bayer, Mannheim, Germany) 48 h post-STZ injection, and
rats with blood glucose $13 mM were considered diabetic. Insulin
was measured by radioimmunoassay kit (BNIBT, Beijing, China).
Serum NO levels were assayed by NO detection kit (Nanjing
Jiancheng Bioengineering Institute, China). The current study was
performed in adherence to the National Institutes of Health
guidelines for the use of experimental animals, and all animal
protocols were approved by the Committee for Ethical Use of
Experimental Animals of the Fourth Military Medical University.
Vascular reactivity
The animals were anesthetized by the intraperitoneal admin-
istration of 20% urethane 8 wk post-injection of STZ or buffer.
Aorta from the heart to the iliac bifurcation was removed and
placed in ice-cold Krebs buffer consisting of (mM): NaCl, 118;
KCl, 4.8; CaCl2?2H2O, 2.5; MgCl2?6H2O, 2.5; NaH2PO4?2H2O,
1.2; NaHCO3, 8.5; and glucose?H2O, 11. The aorta was cleared
of fat, as well as connective tissue, and cut into rings 2 mm long.
The rings were mounted onto hooks, suspended in organ
chambers filled with Krebs buffer, aerated with 95% O2/5%
CO2 at 37uC, and connected to pressure transducers (WPI,
Sarasota, FL) to record the changes via a Mac-Lab recording
system. After 30 min of equilibration at an optimal preload of
9.8 mN, the rings were stimulated with 1 mM of phenylephrine
(PE, Sigma-Aldrich, St. Louis, MO, USA) and 1 mM of
acetylcholine (Ach, Sigma-Aldrich, St. Louis, MO, USA) (both
from Sigma-Aldrich, St. Louis, MO), and rings with .50%
relaxation were considered endothelium-intact. Nitro-L-arginine
methylester (L-NAME, 100 mM, Beyotime Institute of Biotech-
nology, China) [7] and the GPR30-selective antagonist G15
(1 mM, Calbiochem, Germany) [7] were used to pretreat the
vessels of the OVX rats to confirm the role of GPR30 on the
vascular function of rats [3,7]. Since G15 was prepared in
dimethylsulfoxide (DMSO), DMSO was used in all groups with
the same volume in G15 group. The rings were treated as follows:
(1) The roles of eNOS in the GPR30-mediated relaxation were
assessed by plotting concentration-response curves of G1 (1 nM to
100 mM, Cayman Chemical, Ann Arbor, MI) or the vehicle
dimethylsulfoxide (DMSO) in the rings pretreated with or without
L-NAME and G15 in organ chambers; (2) Prior to the detection of
the PE dose-response curves in the rings of OVX and diabetic
OVX rats, some of rings from diabetic OVX rats were first
incubated with L-NAME (100 mM) or G15 (1 mM) for 20 min and
then with G1 (3 mM) for 10 min in organ chambers; (3) The roles
of GPR30 in the vascular function were assessed in the diabetic
OVX rats treated with G1 (200 mg/kg, i.p., 2 times per day) for 8
weeks. The aortic rings were preconstricted with PE in organ
chambers, and the vasorelaxation responses were evaluated with
increasing doses of ACh (10
29 mol/L to 10
25 mol/L). The
maximal effective tension (Emax) was determined with the vascular
response to PE. The maximal vasomotor response was expressed
as a percentage of the contraction induced by 1 mM of PE
(%Rmax for relaxation), and the vascular sensitivity was expressed
as pD2 (2logEC50).
Cell culture and treatments
The aortic endothelial cells (Product ID: RAT-CELL-0008;
PriCell) were maintained in RPMI 1640 medium (HyClone, UT,
USA) supplemented with heat-inactivated fetal bovine serum
(10%), 2 mM of L-glutamine, 100 U/mL of penicillin, and 100 g/
mL of streptomycin. Then, the cells were incubated at 37uCi n5 %
CO2 and 95% air. G1 stock solution was prepared in DMSO and
Figure 7. Activation of eNOS signaling pathway mediated
protective effects of G1. The endothelial cells were treated with high
glucose (HG) for 72 h, and then treated with L-NAME (100 mM) for
40 min and G15 (1 mM) or without them in presence of G1 (10 nM) for
10 min. (A) G1 treatment (10 nM, 10 min) reversed the down-
regulation of phosphorylation level of eNOS by high concentration of
glucose. This effect was blocked by G15. (B) G1 reversed the NO
reduction in endothelial cells exposure to HG. This effect of G1 was
blocked by L-NAME and G15. High concentration of mannitol (33 mM)
did not alter the phosphorylation level of eNOS.
**p,0.01 compared
with the glucose treated before;
#p,0.05,
##p,0.01 compared with
the HG treated;
$p,0.05,
$$p,0.01 compared with the HG+G1 treated.
R e s u l t sa r eg i v e na st h em e a n6 SEM of three independent
experiments.
doi:10.1371/journal.pone.0038787.g007
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and 0.01% DMSO was used as a sham control. The cells were
incubated in serum-free medium for 24 h, and treated with
different concentrations of G1 (10 nM) [33], L-NAME (100 mM)
[34], G15 (1 mM) [35], high glucose (33 mM) and mannitol
(33 mM) at different intervals in the same medium, after which
they were harvested for further analysis. NO levels in culture
medium was assayed by NO detection kit (Nanjing Jiancheng
Bioengineering Institute, China).
Western blot analysis
As described previously [36], equal amounts of proteins (30 mg)
from the cultures or the aortas were separated and electrotrans-
ferred onto the NC membranes (Invitrogen, Carlsbad, USA) that
were probed with anti-eNOS (dilution ratio 1:1000; Cell signaling,
Danvers, MA), anti-phospho-eNOS (Ser
1177, dilution ratio 1:1000;
Cell signaling), Anti-GPR30 antibody (1:250; Abcam) and b-actin
(dilution ratio 1:10000; Sigma-Aldrich, St. Louis, MO) antibodies
diluted in blocking buffer. Each primary antibody was incubated
overnight at 4uC. After 3 washes with Tris-Buffered Saline and
Tween 20 for approximately 15 min, the membranes were
incubated with horseradish peroxidase-conjugated secondary
antibodies (anti-rabbit/anti-mouse immunoglobulin G for the
primary antibodies), and the bands were visualized using an ECL
system (PerkinElmer). The data were pooled from three indepen-
dent experiments.
Immunocytochemistry
The cultured endothelial cells were fixed with ice-cold 4%
paraformaldehyde in PBS (pH 7.4) for 30 min, blocked with 5%
BSA in PBS for 2 h, incubated overnight with primary anti-
GPR30 (1:300) at 4uC, and then incubated with Cy3-conjugated
goat anti-rabbit IgG (Sigma) diluted to 1:100 in blocking solution.
Coverslips were mounted onto slides with 50% glycerin. The
stained samples were photographed and were analyzed using an
Olympus Fluoview FV100 (Olympus, Japan).
Statistical analysis
Data are expressed as mean 6 SEM. Statistical comparisons
were performed using t-test, and the differences between the
multiple groups were assessed using one-way ANOVA. p,0.05
was considered statistically significant.
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